Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Argatroban. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 known ✓ | P00734 | 7/20 | 0.82 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.77 |
| ▸ | F10 | P00742 | 2/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.77 |
| ▸ | PLAT | P00750 | 1/20 | 0.77 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.77 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Argatroban SCHEMBL23356536 | 1.00 | F2 (0.82) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL7279618 | 1.00 | F2 (0.82) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL1133728 | 1.00 | F2 (0.82) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL29501077 | 1.00 | F2 (0.82) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL1470919 | 1.00 | F2 (0.82) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL4374 | 0.99 | F2 (0.83) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL1817517 | 0.99 | F2 (0.83) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL4933701 | 0.99 | F2 (0.83) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL3175687 | 0.99 | F2 (0.83) | F2PRSS1F10LMNAPLAT | |
| Argatroban SCHEMBL1145308 | 0.99 | F2 (0.83) | F2PRSS1F10LMNAPLAT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030114388-A1 | Auxiliary agents for ophthalmic operation | MITSUBISHI PHARMA CORPORATION (JP) | 2003-06-19 | — | — | US | claimed |
| EP-0473502-A1 | Washing composition capable of preventing and ameliorating skin irritation | SHISEIDO COMPANY LIMITED (JP) | 1992-03-04 | — | — | EP | claimed |
| US-9040111-B2 | Method of making a stent | JAPAN STENT TECHNOLOGY CO., LTD. (JP) | 2015-05-26 | — | — | US | disclosed |
| US-8968392-B2 | Method of inhibiting vascular intimal hyperplasia using stent | JAPAN STENT TECHNOLOGY CO., LTD. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-8641756-B2 | Sustained drug-releasing stent | JAPAN STENT TECHNOLOGY CO., LTD. (JP) | 2014-02-04 | — | — | US | disclosed |
| US-8591571-B2 | Drug-eluting stent | JAPAN STENT TECHNOLOGY CO., LTD. (JP) | 2013-11-26 | — | — | US | disclosed |
| US-20130115363-A1 | METHOD OF MAKING A STENT | Iwata, Hiroo (JP) | 2013-05-09 | — | — | US | disclosed |
| US-8409272-B2 | Sustained drug-releasing stent | JAPAN STENT TECHNOLOGY CO., LTD. (JP) | 2013-04-02 | — | — | US | disclosed |
| US-20130018455-A1 | METHOD OF INHIBITING VASCULAR INTIMAL HYPERPLASIA USING STENT | JAPAN STENT TECHNOLOGY CO., LTD. (JP) | 2013-01-17 | — | — | US | disclosed |
| US-20120310329-A1 | SUSTAINED DRUG-RELEASING STENT | JAPAN STENT TECHNOLOGY CO., LTD. (JP) | 2012-12-06 | — | — | US | disclosed |
| US-20100249914-A1 | Sustained drug-releasing stent | JAPAN STENT TECHNOLOGY CO., LTD. | 2010-09-30 | — | — | US | disclosed |
| US-20030114388-A1 | Auxiliary agents for ophthalmic operation | MITSUBISHI PHARMA CORPORATION (JP) | 2003-06-19 | — | — | US | disclosed |
| EP-0565897-B1 | Argatroban preparations for ophthalmic use | MITSUBISHI CHEM CORP (JP) | 2002-06-26 | — | — | EP | disclosed |
| EP-0823430-B1 | Method for preparing n2-arylsulfonyl-l-argininamides | MITSUBISHI CHEM CORP (JP) | 2001-10-24 | — | — | EP | disclosed |
| EP-0608828-B1 | Compositions containing argatroban analogs | MITSUBISHI CHEM CORP (JP) | 2000-03-22 | — | — | EP | disclosed |
| EP-0608831-B1 | Compositions containing argatroban analogs | MITSUBISHI CHEM CORP (JP) | 2000-03-22 | — | — | EP | disclosed |
| EP-0621036-B1 | Aqueous compositions comprising argatroban and cyclodextrin or caffeine | SENJU PHARMA CO (JP) | 1999-03-17 | — | — | EP | disclosed |
| EP-0823430-A1 | Method for preparing n2-arylsulfonyl-l-argininamides | MITSUBISHI CHEMICAL CORPORATION (JP) | 1998-02-11 | — | — | EP | disclosed |
| EP-0621036-A1 | Aqueous compositions comprising argatroban and cyclodextrin or caffeine | Senju Pharmaceutical Co., Ltd. (JP) | 1994-10-26 | — | — | EP | disclosed |
| EP-0565897-A1 | Argatroban preparations for ophthalmic use | Mitsubishi Chemical Corporation (JP) | 1993-10-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018455-A1 | METHOD OF INHIBITING VASCULAR INTIMAL HYPERPLASIA USING STENT | EDNRB, EDNRA, TGFB1 | F2 559/4885PRSS1 185/4885F10 958/4885 |
| US-20030114388-A1 | Auxiliary agents for ophthalmic operation | ASS1, PTMA, ALDH1A2 | F2 47/4885PRSS1 208/4885F10 394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.